Lung cancer is the most common cause of cancer-related deaths. Patients with stage III non-small cell lung cancer may be treated with curative intent. However, there is a high recurrence rate.
The SAKK 16/18 trial seeks to establish whether the prognosis can be improved by immunotherapy and radiotherapy given in addition to the standard treatment. 90 patients with stage III (locally advanced) NSCLC (N2) can join the trial.
For more information on where and how this trial is conducted, consult the trial website.